When was the most recent $MDGL (MADRIGAL PHARMACEUTICALS, INC.) SEC filing?

The latest tracked SEC EDGAR filing for MADRIGAL PHARMACEUTICALS, INC. ($MDGL) was filed on November 3, 2026, with 1 high-impact or featured filings flagged by Position Tracker's AI analysis.

$MDGL SEC EDGAR Filings Hub 1 Filing

$MDGL · MADRIGAL PHARMACEUTICALS, INC. SEC Filings

Q: What SEC filings are tracked for $MDGL (MADRIGAL PHARMACEUTICALS, INC.)?

Position Tracker indexes 1 SEC EDGAR filings for MADRIGAL PHARMACEUTICALS, INC. ($MDGL), including 0 Form 10-K annual reports, 1 Form 10-Q quarterly reports, 0 Form 8-K material event disclosures, and 0 Form 4 insider buying and selling filings.

Position Tracker tracks 1 SEC EDGAR filings for MADRIGAL PHARMACEUTICALS, INC. ($MDGL) from November 3, 2026 through November 3, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 0 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.

Check $MDGL portfolio concentration → View $MDGL Congress trades → Research $MDGL stock → All SEC filings →

Total Filings1

10-K / 10-Q Reports1

8-K Material Events0

Form 4 Insider0

High-Impact1

Latest FilingNovember 3, 2026

Browse SEC Filings by Form Type

Form 4 Form 8-K Form 10-K Form 10-Q Schedule 13D/13G Form 13F Form S-1 Form 6-K

Latest $MDGL SEC Filings & AI Summaries (1)

$MDGL Form 10-Q Impact 8/10 Earnings

November 3, 2026

$MDGL 10-Q — MADRIGAL PHARMACEUTICALS, INC.

Madrigal's first profitable quarter validates the commercial viability of the only FDA-approved MASH drug, with Rezdiffra revenue accelerating 50% YoY to a $1.7B+ annualized run…

Read AI filing analysis → SEC.gov filing ↗

$MDGL · MADRIGAL PHARMACEUTICALS, INC. SEC Filings

$MDGL 10-Q — MADRIGAL PHARMACEUTICALS, INC.

Get real-time alerts when $MDGL files a new 10-K, 10-Q, 8-K, or Form 4.